Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease-Reference-Cited by-同舟云学术

Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease

Published:2019-02 Issue:4 Volume:12 Page:411-412
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Collet Carlos,Modolo Rodrigo,Banning Adrian,Kandzari David E.,Stables Rod,Dressler Ovidiu,Sabik Joseph F.,Kappetein A. Pieter,Stone Gregg W.,Serruys Patrick W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference3 articles.

1. Staging of multivessel percutaneous coronary interventions: an expert consensus statement from the Society for Cardiovascular Angiography and Interventions;Blankenship;Catheter Cardiovasc Interv,2012

2. Everolimus-eluting stents or bypass surgery for left main coronary artery disease;Stone;N Engl J Med,2016

3. Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study;Watkins;EuroIntervention,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease–2;American Heart Journal;2023-02

2. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design;American Heart Journal;2022-04

3. Ten-year all-cause mortality following staged percutaneous revascularization in patients with complex coronary artery disease;Cardiovascular Revascularization Medicine;2021-09

4. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS);The American Journal of Cardiology;2021-01

5. A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial;EuroIntervention;2020-12